Completed PHASE2 INTERVENTIONAL 1-arm NCT03469713

Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma (NIVES)

Nivolumab Plus Stereotactic Body Radiotherapy (SBRT) in II and III Line of Patients With Metastatic Renal Cell Carcinoma (mRCC)

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Conditions Renal Cancer Metastatic

Interventions Nivolumab

Updated 8 times since 2018 Last updated: May 1, 2022 Started: Jul 14, 2017 Primary completion: Mar 4, 2019 Completion: Jul 14, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Renal Cancer Metastatic and is currently completed. Gruppo Oncologico Italiano di Ricerca Clinica leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2021 — Jun 2022 [monthly]

Active Not Recruiting PHASE2
Aug 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Sep 2018 — Aug 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gruppo Oncologico Italiano di Ricerca Clinica

Data source: Gruppo Oncologico Italiano di Ricerca Clinica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reggio Emilia, Italy